The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer

Cancer ◽  
2007 ◽  
Vol 110 (2) ◽  
pp. 363-368 ◽  
Author(s):  
Steven E. Schild ◽  
Sumithra J. Mandrekar ◽  
Aminah Jatoi ◽  
William L. McGinnis ◽  
Phillip J. Stella ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Cell Lung Cancer ◽  
Combined Modality Therapy ◽  
Nonsmall Cell Lung Cancer ◽  
Stage Iii ◽  
Combined Modality

Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer.

1996 ◽  
Vol 14 (5) ◽  
pp. 1642-1648 ◽  
Author(s):  
F A Greco ◽  
S L Stroup ◽  
J R Gray ◽  
J D Hainsworth
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Combined Modality Therapy ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Combined Modality ◽  
Grade 3

PURPOSE The addition of combination chemotherapy to standard radiation therapy has improved treatment for locally unresectable non-small-cell lung cancer. In this phase II study, we evaluated the toxicity and efficacy of a novel chemotherapy regimen that included paclitaxel, cisplatin, and etoposide plus concurrent radiation therapy in this group of patients. PATIENTS AND METHODS Thirty-three patients with previously untreated, unresectable stage III non-small-cell lung cancer (stage IIIA, 11 patients; stage IIIB, 22 patients) initially received two courses of chemotherapy, which included paclitaxel 135 mg/m2 by 1-hour infusion on day 1, cisplatin 60 mg/m/ intravenously (i.v.) on day 2, and etoposide 100 mg/m2 i.v. on days 1, 2 and 3. On week 6, radiation therapy (60 Gy in 30 fractions) was initiated in conjunction with two additional courses of chemotherapy: paclitaxel 135 mg/m2 i.v. by 1-hour infusion on day 1, cisplatin 5 mg/m2 i.v. on days 2- to 10, and etoposide 25 mg/m2 on days 1 to 10. RESULTS This combined modality program was feasible and well tolerated by most patients. During the two courses of induction chemotherapy, grade 3 or 4 myelosuppression occurred in only six patients (18%). Esophagitis was common during combined modality therapy (grade 3, 10 patients; grade 4 five patients). Forty-two percent of patients had partial response after two courses of induction therapy, and 82% of patients had an objective response at completion of therapy. Twelve patients (36%) had a complete response. Nineteen patients remain progression-free at a median of 8 months; the median survival time has not been reached. CONCLUSION This paclitaxel-containing combined modality therapy is feasible and highly active in patients with inoperable stage III lung cancer. Esophagitis is the most common severe toxicity with this program. Further studies with paclitaxel-containing combination regimens in patients with stage III non-small-cell lung cancer are indicated.

O-95 Combined modality therapy in a population-based cohort of patients with stage III Non-small cell lung cancer

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S31
Author(s):  
Elaine S. Wai ◽  
Veronika Moravan ◽  
Pauline Truong ◽  
Eric Berthelet ◽  
Jan T.W. Lim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Combined Modality Therapy ◽  
Population Based ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Combined Modality
Sign in / Sign up

Export Citation Format

Share Document